Cutaneous complications of Anderson-Fabry disease

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Anderson-Fabry disease is an X-linked lysosomal storage disorder caused by a defect in the α-galactosidase A gene, which leads to the deficiency of the hydrolytic enzyme α-galactosidase A. The consequent inability to catabolize glycosphingolipids causes progressive accumulation of globotriaosylceramide in the vascular endothelium throughout the body. Fatalities in the classical phenotype may usually occur as a consequence of cerebral, cardiac or renal disease. Dermatological manifestations are a relevant feature of Fabry disease and include angiokeratomas, telangiectasiae, lymphedema, anhidrosis or hypohidrosis and pseudo-acromegalic facial appearance. The actual causal treatment for Fabry disease is the enzyme replacement therapy. Dermatologists have a key role, since cutaneous manifestations may lead to the diagnosis. This may help an early therapeutic intervention, reducing both morbidity and mortality.
Original languageEnglish
Pages (from-to)6031-6036
Number of pages6
JournalCURRENT PHARMACEUTICAL DESIGN
Volume19
Publication statusPublished - 2013

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Cutaneous complications of Anderson-Fabry disease'. Together they form a unique fingerprint.

Cite this